Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01929343
Other study ID # STU 032013-049
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 2014
Est. completion date March 2016

Study information

Verified date December 2020
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We propose that the systemic administration of lidocaine following the induction of cue-induced craving, relative to saline plus cue-induced craving or lidocaine without cue-induced craving, will block the reconsolidation of cue memories. This will lead to a reduction in cue-induced craving upon repeated testing as well as subsequent cocaine use and basal craving.


Description:

Cocaine dependence is among the most tenacious of the substance use disorders yet remains one of the few lacking an effective pharmacological intervention. As other pharmacologic approaches have not been fruitful, new targets are required. A novel treatment approach is to disrupt the neural processes involved in cue-related memories (memory links between the external stimuli associated with drug use and the subjective drug effect). These engrained memories, when reactivated by cues, elicit craving and a return to drug use. Each cue re-exposure, however, requires the re-remembering (or reconsolidation) of the drug cue. Key molecular processes required for memory reconsolidation are NMDA (N-methyl-D-aspartate) receptor activation, the induction of nitric oxide (NO) synthesis and increased extracellular signal-regulated kinase (ERK) activity. In rodent models, blocking these processes changes the cue-related memory; the cue loses its potency to induce a return to drug self-administration. Lidocaine is an FDA (Food and Drug Administration) approved medication that inhibits activation of NMDA (N-methyl-D-aspartate) receptors and suppresses production of NO (nitric oxide) and ERK (extracellular signal-regulated kinase). Lidocaine, like cocaine, is a local anesthetic with potent effects as a sodium-channel blocker. Unlike cocaine, lidocaine is essentially devoid of activity at monoamine re-uptake transporters and has no rewarding or addictive properties. As lidocaine suppresses the molecular processes required for drug cue reconsolidation and has relatively specific effects upon the striatal regions necessary for drug cue reconsolidation, lidocaine may offer a novel approach for interfering with memory reconsolidation. Two other (Sodium) Na+ channel blockers have also decrease craving and/or substance use in substance-dependent subjects. We propose that the systemic administration of lidocaine following the induction of cue-induced craving, relative to saline plus cue-induced craving or lidocaine without cue-induced craving, will block the reconsolidation of cue memories. This will lead to a reduction in cue-induced craving upon repeated testing as well as subsequent cocaine use and basal craving. If our hypotheses are proven correct, these findings will 1) support a role for lidocaine in cocaine addiction treatment, 2) demonstrate the feasibility and efficacy of attenuating cue-induced memories, and 3) guide the development of a larger study with lidocaine.


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender All
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria: - 25-60 years old - men or women - any race or ethnicity - cocaine addition is primary present and lifetime drug of abuse - live locally Exclusion Criteria: - Patients with active DSM (Diagnostic Statistical Manual)-IV other Substance Dependence (except nicotine) within the previous three months, Affective Disorder, Schizophrenic Disorders. - significant cognitive impairment (WTAR<70) (Wechsler Test of Adult Reading <70).. - use of tricyclic anti-depressants, benzodiazepines, cimetidine, mood stabilizers, opioids, lithium, sympathomimetics, anticonvulsants, sedative/hypnotics, ß-blockers, or dopamine agonists will be excluded from the study. - Medical conditions that might limit cooperation (e.g. dementia) or put the patient at medical risk (i.e. significant hematologic, hepatic, renal, or cardiovascular pathology - particularly arrhythmias) will be excluded. - Patients with congenital or idiopathic methemoglobinemia or patients taking medications associated with increased risk of methemoglobinemia (including sulfonamides, acetaminophen, acetanilid, aniline dyes, benzocaine, chloroquine, dapsone, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, paraaminosalicylic acid, phenacetin, phenobarbital, phenytoin, primaquine, quinine) will be excluded. - Patients with past or present neurologic disorders (i.e. severe head trauma, transient ischemic attacks, stroke, tumor, etc.) will be excluded. - Active suicidal ideation, pregnant or nursing women, and prisoners will be excluded from the study.

Study Design


Intervention

Drug:
lidocaine following cue-induced craving
as described in Arm Description
lidocaine following neutral stimulus
as described in Arm Description
saline
as described in Arm Description

Locations

Country Name City State
United States UT Southwestern Medical Center at Dallas, Division on Addictions Dallas Texas

Sponsors (2)

Lead Sponsor Collaborator
Bryon Adinoff National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cue-induced Craving After Lidocaine/Saline Administration. 7 days after lidocaine/saline administration, cocaine craving will be measured during the administration of relaxation or craving script. Craving intensity will be measured by the subjective intensity of craving as reported by the participant. Measured via a visual analog scale based on 4 (out of 10) questions from the Cocaine Craving Questionnaire (1-strongly disagree to 7- strongly agree). Highest total score possible 28, lowest score possible is 4. If the score is low in the lidocaine group and high in the saline group, it would mean that lidocaine has successfully decreased the craving response relative to saline. craving measured immediately following reading of the script.
Primary Physiological Responses as Measured by Heart Rate After Lidocaine/Saline Administration. 7 days after lidocaine/saline administration, heart rate will be measured during the administration of a relaxation or craving script. Heart rate will be measured in beats per minute. 120 seconds, during reading of the script.
Primary Physiological Responses as Measured by Blood Pressure After Lidocaine/Saline Administration. 7 days after lidocaine/saline administration, blood pressure (BP) response will be assessed during relaxation or craving script. Blood pressure will be measured by mmHg. BP will measured during the two minutes of script reading.
Primary Physiological Responses as Measured by Galvanic Skin Response (GSR) After Lidocaine/Saline Administration. 7 days after lidocaine/saline administration, GSR will be measured during the reading of the relaxation or saline script. It is predicted that higher GSR would be associated with higher cocaine craving and lower GSR will be associated with lower cocaine craving. 2 minutes during script reading.
Primary Physiological Responses as Measured by EMG (Electromyography) After Lidocaine/Saline Administration. Electromyography (frontal) will be measured during the administration of the relaxation or craving script seven days after infusion. EMG is assessed by uV (microvolts). Higher scores reflect greater amounts of EMG activity, lower scores reflect lower amounts of EMG activity. It was expected that EMG would be positively associated with cocaine craving. 2 minutes during administration of script.
Secondary Cocaine Use cocaine use will be measured by urine drug screen and participant self-report three times weekly after lidocaine/saline administration. Cocaine use will be assessed as positive (1) or negative (0) using urine drug screen for cocaine and/or by participant self-report of cocaine use. cocaine use will be measure during the 4 weeks following infusion
Secondary Cocaine Craving basal measures of cocaine craving will be measured by Cocaine Craving Questionnaire (CCQ) times weekly after lidocaine/saline administration. The higher the score the more craving and lower the score the less craving. The CCQ has 10 items, each item scored 1-7. Maximum score is 70, minimum score is 7. cocaine craving will be measure during the 4 weeks following infusion
See also
  Status Clinical Trial Phase
Completed NCT04336293 - sTMS for Substance Use-disordered Veterans N/A
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT01822587 - Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving Phase 2
Completed NCT01601743 - Exercise as a Behavioral Treatment for Cocaine Dependence N/A
Completed NCT02563769 - Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study Phase 1
Completed NCT01651377 - Pramipexole as a Treatment for Cocaine Dependence Phase 1
Completed NCT02768441 - Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots Early Phase 1
Completed NCT02626494 - Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Phase 4
Recruiting NCT02892851 - Deep Brain Stimulation of the Sub-Thalamic Nucleus to Treat Severe and Treatment-resistant Cocaine Addiction. N/A
Not yet recruiting NCT01319214 - Reducing Drug Craving Memories N/A
Recruiting NCT01259362 - Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients Phase 2
Completed NCT01211418 - Integrative Meditation (IM) for Cocaine Addiction N/A
Recruiting NCT03423667 - Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction Phase 2
Completed NCT01887366 - Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects Phase 2
Completed NCT01984177 - Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence N/A
Completed NCT01337297 - Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction Phase 1/Phase 2
Completed NCT01067846 - Cognitive Enhancement and Relapse Prevention in Cocaine Addiction N/A
Completed NCT01651364 - A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence Phase 1
Recruiting NCT03018236 - Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Phase 4
Completed NCT01281202 - Vigabatrin for the Treatment of Cocaine Dependency Phase 2/Phase 3